SillaJen, Inc.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureSillaJen, Inc. was founded in March 2006 to develop anticancer drugs and listed on the KOSDAQ market in December 2016. The company is developing the oncolytic virus immunotherapy Pexa-Vec and mitotic checkpoint inhibitors targeting TTK and PLK1, while its pharmaceutical division has obtained approval for and markets five injectable prescription products. Pexa-Vec's Phase 3 hepatocellular carcinoma trial (PHOCUS) was terminated early on August 2, 2019, and SillaJen also operates an anticancer drug development and commerce business alongside its prescription drug R&D and sales division.
Products & technology
- Pexa-VecOncolytic virus immunotherapy under development for multiple solid tumors
- 프로파인퓨전주Injectable prescription drug
- 뉴아미노펜프리믹스주Injectable prescription drug
- 이브포프리믹스주Injectable prescription drug
- 페라미비르주Injectable prescription drug
- 펜타블루5주Injectable prescription drug
Regulatory approvals
data.go.kr1 Korean MFDS drug approvals · 2021
- MFDS drugNewpropa Injection2021-03-15Drug · Prescription · Approval202102323
Clinical trials
data.go.kr3 MFDS clinical trial authorisations · 2015–2023 (Phase 1 2 · Phase 3 1)
- Phase 1BAL08912023-04-12
12 trial sites
- Phase 3Pexa-Vec(Pexastimogene Devacirepvec)2016-04-29
20 trial sites
- Phase 1SJ-103β2015-09-11
1 trial site
R&D and key agreements
Source: DART corporate disclosure펙사벡(Pexa-Vec) · 간암 등 고형암 · 임상 3상(PHOCUS, 간암, 조기종료) · The Phase 3 trial (PHOCUS) for hepatocellular carcinoma was terminated early on August 2, 2019.
유사분열 체크포인트 억제제(MCI) · 연구개발 진행중 · Under development to inhibit TTK and PLK1 kinases and disrupt the cancer cell cycle.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
KOSDAQ-listed biopharma developing the BVAC cancer immunotherapy vaccine series and the AdCLD-CoV19-1 COVID-19 vaccine.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition